FFC#1/2016

New generation trimethylangelicin (TMA) analogues for selective modulation of defective CFTR or inflammation

AREA 1 Therapies to correct the underlying defect

FFC#1/2016

New generation trimethylangelicin (TMA) analogues for selective modulation of defective CFTR or inflammation
€ 0 still needed
0%
€ 80.000 goal

pRINCIPAL INVESTIGATOR

Adriana Chilin (Dipartimento di Scienze Farmaceutiche e Farmacologiche, Università di Padova)

Researchers

9

Category

AREA 1 Therapies to correct the underlying defect

Duration

2 years

Goal

€ 80.000

Funds raised

€ 80.000

Objectives

Starting from the two prototype TMA analogues identified preliminarly, the project deals with the design, synthesis and biological evaluation of optimized derivatives of the two lead compounds selected from the first library of TMA analogues. The goals of the project can be outlined in 5 sections: 1) design and synthesis of new TMA analogues; 2) evaluation of phototoxicity and mutagenicity; 3) testing of the anti-inflammatory activity; 4) testing of the effects as CFTR function modulators; 5) derivation of structure-activity relationships aimed at a full comprehension of the structural determinants required to obtain selective properties.

WHO ADOPTED THE PROJECT

Delegazione FFC di Rovigo

€ 8.000

Delegazione FFC di Boschi Sant’Anna Minerbe

€ 20.000

Guadagnin srl

€ 8.000

Delegazione FFC del Lago di Garda con i Gruppi di Sostegno di Arezzo, dell’Isola Bergamasca, di Chivasso

€ 44.000

Delegazione FFC di Boschi Sant’Anna Minerbe

€ 20.000

Guadagnin srl

€ 8.000

OTHER PROJECTS

Discover the other projects

GMRF#1/2026

Exploring the role of PKD1 in promoting CFTR stability and function at the cell surface

FFC#1/2026

Mapping proteins regulating CFTR mRNA stability to identify new therapeutic targets for nonsense mutations

FFC#2/2026

Evaluating the potential of phosphodiesterase inhibitors to enhance the efficacy of CFTR modulators and support personalized therapeutic approaches